Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
IntroductionBevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is widely used as a first-line treatment for metastatic colorectal cancer (mCRC), with hypertension being a common adverse effect. However, there is limited data on the predisposing factors contributing to bevacizumab-in...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Liburua |
| Argitaratua: |
Frontiers Media S.A.,
2024-10-01T00:00:00Z.
|
| Gaiak: | |
| Sarrera elektronikoa: | Connect to this object online. |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Sailkapena: |
A1234.567 |
|---|---|
| Alea 1 | Eskuragarri |